{"name":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","slug":"gruppo-italiano-per-lo-studio-dei-carcinomi-dell-apparato-digerente","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bevacizumab and FOLFIRI","genericName":"Bevacizumab and FOLFIRI","slug":"bevacizumab-and-folfiri","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Irinotecan/Cetuximab","genericName":"Irinotecan/Cetuximab","slug":"irinotecan-cetuximab","indication":"Metastatic colorectal cancer, EGFR-positive or wild-type KRAS","status":"phase_3"}]}],"pipeline":[{"name":"Bevacizumab and FOLFIRI","genericName":"Bevacizumab and FOLFIRI","slug":"bevacizumab-and-folfiri","phase":"phase_2","mechanism":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Irinotecan/Cetuximab","genericName":"Irinotecan/Cetuximab","slug":"irinotecan-cetuximab","phase":"phase_3","mechanism":"Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity.","indications":["Metastatic colorectal cancer, EGFR-positive or wild-type KRAS","Advanced colorectal cancer as first-line or later-line therapy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}